Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

References

• CitromeLEmerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?CNS Spectr201621S1112
   PubMed Web of Science ®Google Scholar
• LeuchtSCiprianiASpineliLComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet2013382989695196223810019
   PubMed Web of Science ®Google Scholar
• VolavkaJCitromeLOral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-makingExpert Opin Pharmacother200910121917192819558339
   PubMed Web of Science ®Google Scholar
• CitromeLUnmet needs in the treatment of schizophrenia: new targets to help different symptom domainsJ Clin Psychiatry201475Suppl 1212624581451
   PubMed Web of Science ®Google Scholar
• CitromeLEramoAFrancoisCLack of tolerable treatment options for patients with schizophreniaNeuropsychiatr Dis Treat2015113095310426719694
   PubMed Web of Science ®Google Scholar
• Cariprazine DrugFDAPackage;Approval2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig2s000TOC.cfmAccessed July 4, 2018
   Google Scholar
• European Medicines AgencyReagila Assessment Report2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002770/WC500234926.pdfAccessed July 4, 2018
   Google Scholar
• CitromeLThe ABC’s of dopamine receptor partial agonists – aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents outInt J Clin Pract201569111211122026477545
   PubMed Web of Science ®Google Scholar
• CitromeLAripiprazole, brexpiprazole, and cariprazine: not all the sameCurrent Psychiatry2018174243343
   Google Scholar
• AllerganVRAYLAR (cariprazine) capsules, for oral use2017 Available from: https://www.allergan.com/assets/pdf/vraylar_piAccessed July 4, 2018
   Google Scholar
• CitromeLCariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial AgonistClin Schizophr Relat Psychoses201610210911927440212
   PubMedGoogle Scholar
• CitromeLCariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapyAdv Ther201330211412623361833
   PubMed Web of Science ®Google Scholar
• CitromeLCariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerabilityExpert Opin Drug Metab Toxicol20139219320623320989
   PubMed Web of Science ®Google Scholar
• DurgamSLitmanREPapadakisKLiDNémethGLaszlovszkyICariprazine in the treatment of schizophrenia: a proof-of-concept trialInt Clin Psychopharmacol2016312616826655732
   PubMed Web of Science ®Google Scholar
• DurgamSStaraceALiDAn evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trialSchizophr Res20141522–345045724412468
   PubMed Web of Science ®Google Scholar
• KaneJMZukinSWangYEfficacy and Safety of cariprazine in acute exacerbation of schizophrenia: results from an international, Phase III clinical trialJ Clin Psychopharmacol201535436737326075487
   PubMed Web of Science ®Google Scholar
• DurgamSCutlerAJLuKCariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trialJ Clin Psychiatry20157612e1574e158226717533
   PubMed Web of Science ®Google Scholar
• NakamuraTKubotaTIwakajiAImadaMKapásMMorioYClinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)Drug Des Devel Ther201610327338
   PubMed Web of Science ®Google Scholar
• DurgamSEarleyWLiRCorrigendum to “Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial” [Schizophr Res. 176 (2016) 264–271]Schizophr Res201819249328427929
   PubMed Web of Science ®Google Scholar
• EarleyWGuoHLuchiniRModified cariprazine relapse prevention clinical trial resultsSchizophr Res Epub2018426
   Web of Science ®Google Scholar
• DurgamSGreenbergWMLiDSafety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension studyPsychopharmacology2017234219920927807604
   PubMed Web of Science ®Google Scholar
• CutlerAJDurgamSWangYEvaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label studyCNS Spectr2018231395028478771
   PubMed Web of Science ®Google Scholar
• NasrallahHAEarleyWCutlerAJThe safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysisBMC Psychiatry201717130528836957
   PubMed Web of Science ®Google Scholar
• EarleyWDurgamSLuKLaszlovszkyIDebelleMKaneJMSafety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studiesInt Clin Psychopharmacol201732631932828692485
   PubMed Web of Science ®Google Scholar
• CitromeLDurgamSLuKFergusonPLaszlovszkyIThe effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trialsJ Clin Psychiatry201677110911526845266
   PubMed Web of Science ®Google Scholar
• DurgamSEarleyWLuKGlobal improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysisInt J Clin Pract20177112e13037
   Web of Science ®Google Scholar
• NémethGLaszlovszkyICzoborPCariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trialLancet2017389100741103111328185672
   PubMed Web of Science ®Google Scholar
• NémethBMolnárAAkehurstRQuality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidoneJ Comp Eff Res20176863964828511548
   PubMed Web of Science ®Google Scholar
• MészárosGPAgai-CsongorEKapásMSensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urineJ Pharm Biomed Anal200848238839718242914
   PubMed Web of Science ®Google Scholar
• KissBHorváthANémethyZCariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profileJ Pharmacol Exp Ther2010333132834020093397
   PubMed Web of Science ®Google Scholar
• SenecaNFinnemaSJLaszlovszkyIOccupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomographyPsychopharmacology2011218357958721625907
   PubMed Web of Science ®Google Scholar
• GyertyánIKissBSághyKCariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodentsNeurochem Int201159692593521767587
   PubMed Web of Science ®Google Scholar
• TadoriYForbesRAMcquadeRDKikuchiTIn vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptorsEur J Pharmacol2011668335536521816144
   PubMed Web of Science ®Google Scholar
• Agai-CsongorEDományGNógrádiKDiscovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptorsBioorg Med Chem Lett201222103437344022537450
   PubMed Web of Science ®Google Scholar
• ZimniskyRChangGGyertyánIKissBAdhamNSchmaussCCariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mousePsychopharmacology201322619110023079899
   PubMed Web of Science ®Google Scholar
• RománVGyertyánISághyKKissBSzombathelyiZCariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in ratsPsychopharmacology2013226228529323138433
   PubMed Web of Science ®Google Scholar
• TóthMVarroneASteigerCBrain uptake and distribution of the dopamine D3/D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primatesSynapse201367525826423238770
   PubMed Web of Science ®Google Scholar
• ShonbergJHerenbrinkCKLópezLA structure-activity analysis of biased agonism at the dopamine D2 receptorJ Med Chem201356229199922124138311
   PubMed Web of Science ®Google Scholar
• PappMGrucaPLasoń-TyburkiewiczMAdhamNKissBGyertyánIAttenuation of anhedonia by cariprazine in the chronic mild stress model of depressionBehav Pharmacol2014255–656757425083572
   PubMed Web of Science ®Google Scholar
• ChoiYKAdhamNKissBGyertyánITaraziFILong-term effects of cariprazine exposure on dopamine receptor subtypesCNS Spectr201419326827724229617
   PubMed Web of Science ®Google Scholar
• HendrickCEWangQSynthesis of ortho-haloaminoarenes by aryne insertion of nitrogen-halide bondsJ Org Chem20158021059106925495648
   PubMed Web of Science ®Google Scholar
• El-MallakhRSPayneRSSchurrACariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slicesPsychiatry Res20152291–237037326160196
   PubMed Web of Science ®Google Scholar
• GaoYPetersonSMasriBCariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactionsPharmacol Res Perspect201531e0007325692006
   PubMedGoogle Scholar
• NeillJCGraysonBKissBGyertyánIFergusonPAdhamNEffects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatologyEur Neuropsychopharmacol201626131426655189
   PubMed Web of Science ®Google Scholar
• GirgisRRSlifsteinMD’SouzaDPreferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNOPsychopharmacology201623319–203503351227525990
   PubMed Web of Science ®Google Scholar
• WatsonDJGKingMVGyertyánIKissBAdhamNFoneKCFThe dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophreniaEur Neuropsychopharmacol201626220822426723167
   PubMed Web of Science ®Google Scholar
• DuricVBanasrMFranklinTCariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress ModelInt J Neuropsychopharmacol2017201078879628531264
   PubMed Web of Science ®Google Scholar
• ChoiYKAdhamNKissBGyertyánITaraziFILong-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazineCNS Spectr201722648449428059046
   PubMed Web of Science ®Google Scholar
• BarnesSAYoungJWMarkouAAdhamNGyertyánIKissBThe Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time TaskPsychopharmacology2018235551403141429473089
   PubMed Web of Science ®Google Scholar
• KehrJYoshitakeTIchinoseFEffects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activityPsychopharmacology201823551593160729637288
   PubMed Web of Science ®Google Scholar
• Genaro-MattosTCTallmanKAAllenLBDichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesisToxicol Appl Pharmacol2018349212829698737
   PubMed Web of Science ®Google Scholar
• DelcourteSAshbyCRRoveraRThe novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activityCNS Neurosci Ther Epub201854
   Web of Science ®Google Scholar
• DurgamSStaraceALiDThe efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trialBipolar Disord2015171637525056368
   PubMed Web of Science ®Google Scholar
• SachsGSGreenbergWMStaraceACariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trialJ Affect Disord201517429630225532076
   PubMed Web of Science ®Google Scholar
• CalabreseJRKeckPEStaraceAEfficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled studyJ Clin Psychiatry201576328429225562205
   PubMed Web of Science ®Google Scholar
• KetterTASachsGSDurgamSThe safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: a 16-week open-label studyJ Affect Disord201822535035628843918
   PubMed Web of Science ®Google Scholar
• EarleyWDurgamSLuKTolerability of cariprazine in the treatment of acute bipolar I mania: a pooled post hoc analysis of 3 phase II/III studiesJ Affect Disord201721520521228343051
   PubMed Web of Science ®Google Scholar
• VietaEDurgamSLuKRuthADebelleMZukinSEffect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II/III trialsEur Neuropsychopharmacol201525111882189126419293
   PubMed Web of Science ®Google Scholar
• EarleyWDurgamSLuKClinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorderJ Affect Disord201822623924429017067
   PubMed Web of Science ®Google Scholar
• DurgamSEarleyWLipschitzAAn 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depressionAm J Psychiatry2016173327128126541814
   PubMed Web of Science ®Google Scholar
• DurgamSEarleyWGuoHEfficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorderJ Clin Psychiatry201677337137827046309
   PubMed Web of Science ®Google Scholar
• LaoKSHeYWongICBesagFMChanEWTolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled TrialsCNS Drugs201630111043105427550371
   PubMed Web of Science ®Google Scholar
• CorponiFSerrettiAMontgomerySFabbriCCariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trialsInt Clin Psychopharmacol201732630931828727644
   PubMed Web of Science ®Google Scholar
• ZhaoMJQinBWangJBEfficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled TrialsJ Clin Psychopharmacol2018381555929257786
   PubMed Web of Science ®Google Scholar
• MeyerJMLoebelADSchweizerELurasidone: a new drug in development for schizophreniaExpert Opin Investig Drugs2009181117151726
   PubMed Web of Science ®Google Scholar
• StahlSMDrugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypesCNS Spectr201722537538428965530
   PubMed Web of Science ®Google Scholar
• StahlSMDazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptorsCNS Spectr201722430531128758887
   PubMed Web of Science ®Google Scholar
• ShayeKAmirTShlomoSYechezkelSFasting glucose levels within the high normal range predict cardiovascular outcomeAm Heart J2012164111111622795290
   PubMed Web of Science ®Google Scholar
• AllerganAllergan Receives FDA Approval For Use of VRAYLAR (cariprazine) in the Maintenance Treatment of Schizophrenia2017 Available from: https://www.allergan.com/news/news/thomson-reuters/allergan-receives-fda-approval-for-use-of-vraylarAccessed July 6, 2018
   Google Scholar
• CitromeLSchizophrenia relapse, patient considerations, and potential role of lurasidonePatient Prefer Adherence2016101529153727563237
   PubMed Web of Science ®Google Scholar
• WeidenPJKimEBermakJTurkozIGopalSBerwaertsJDoes Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of PaliperidoneJ Clin Psychiatry2017787e813e82028640988
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyReagila Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002770/WC500234924.pdfAccessed July 6, 2018
   Google Scholar
• EdgarCJBlaettlerTBugarski-KirolaDLe ScouillerSGaribaldiGMMarderSRReliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptomsPsychiatry Res20142181–221922424809242
   PubMed Web of Science ®Google Scholar
• CitromeLNasrallahHAOn-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does notExpert Opin Pharmacother201213111599161322017361
   PubMed Web of Science ®Google Scholar
• CitromeLQuantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medicationsCurr Drug Saf20094322923719534647
   PubMedGoogle Scholar
• CitromeLActivating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to HarmJ Clin Psychopharmacol201737213814728141623
   PubMed Web of Science ®Google Scholar
• CitromeLJohnstonSNadkarniASheehanJJKamatSAKalsekarIPrevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and Medicaid insured patients newly initiating atypical antipsychoticsCurr Drug Saf20149322723524909573
   PubMedGoogle Scholar